← Back to Search

Monoclonal Antibodies

Bimekizumab for Ankylosing Spondylitis (BE AGILE 2 Trial)

Phase 2
Waitlist Available
Research Sponsored by UCB Biopharma SRL
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from entry visit (visit 1) until last visit (up to week 208)
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying the safety and tolerability of bimekizumab in people with ankylosing spondylitis. Bimekizumab helps reduce inflammation and pain by blocking proteins that cause these symptoms. It has shown promise in early studies for treating psoriatic disease and ankylosing spondylitis.

Eligible Conditions
  • Ankylosing Spondylitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from entry visit (visit 1) until last visit (up to week 208)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from entry visit (visit 1) until last visit (up to week 208) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of serious adverse event (SAE) during the study
Incidence of treatment-emergent adverse events (TEAEs) during the study
Secondary study objectives
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) to Week 48
Subjects who withdrew due to an treatment-emergent adverse event (TEAE) during the study
Subjects with Axial Spondyloarthritis International Society 20 % response criteria (ASAS20) at Week 48 calculated relative to Baseline of AS0008
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BimekizumabExperimental Treatment1 Intervention
Subjects will receive bimekizumab up to 4 years.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bimekizumab
2018
Completed Phase 3
~6510

Find a Location

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor
113 Previous Clinical Trials
22,894 Total Patients Enrolled
UCB CaresStudy Director001 844 599 2273
216 Previous Clinical Trials
46,236 Total Patients Enrolled
~32 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top